Endothelin-receptor antagonists for aneurysmal subarachnoid hemorrhage: An updated meta-analysis of randomized controlled trials

Critical Care

Volumn 16, Issue 5, 2012, Pages

  Ma, Junpeng ^a   Huang, Siqing ^a   Ma, Lu ^a   Liu, Yi ^a   Li, Hao ^a   You, Chao ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CLAZOSENTAN; ENDOTHELIN RECEPTOR ANTAGONIST; TAK 044;

ANEMIA; ARTICLE; BRAIN ANGIOGRAPHY; BRAIN HEMORRHAGE; BRAIN INFARCTION; BRAIN VASOSPASM; DRUG EFFICACY; HEART MUSCLE ISCHEMIA; HEPATOBILIARY DISEASE; HUMAN; HYPOTENSION; LUNG COMPLICATION; META ANALYSIS; MORTALITY; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK; SUBARACHNOID HEMORRHAGE; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 84867562887     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc11686     Document Type: Article

References (31)

1. Suarez JI, Tarr RW, Selman WR. Aneurysmal subarachnoid hemorrhage. N Engl J Med 2006, 354:387-396. 10.1056/NEJMra052732, 16436770.
2. de Rooij NK, Linn FH, van der Plas JA, Algra A, Rinkel GJ. Incidence of subarachnoid haemorrhage: a systematic review with emphasis on region, age, gender and time trends. J Neurol Neurosurg Psychiatry 2007, 78:1365-1372. 10.1136/jnnp.2007.117655, 2095631, 17470467.
3. Hackett ML, Anderson CS. Health outcomes 1 year after subarachnoid hemorrhage. An international population-based study. Neurology 2000, 55:658-662. 10.1212/WNL.55.5.658, 10980729.
4. Mayer SA, Kreiter KT, Copeland D, Bernardini GL, Bates JE, Peery S, Claassen J, Du YE, Connolly ES. Global and domain-specific cognitive impairment and outcome after subarachnoid hemorrhage. Neurology 2002, 59:1750-1758. 10.1212/01.WNL.0000035748.91128.C2, 12473764.
5. Nieuwkamp DJ, Setz LE, Algra A, Linn FH, de Rooij NK, Rinkel GJ. Changes in case fatality of aneurysmal subarachnoid haemorrhage over time, according to age, sex, and region: a meta-analysis. Lancet Neurol 2009, 8:635-642. 10.1016/S1474-4422(09)70126-7, 19501022.
6. Crowley RW, Medel R, Kassell NF, Dumont AS. New insights into the causes and therapy of cerebral vasospasm following subarachnoid hemorrhage. Drug Discov Today 2008, 13:254-260. 10.1016/j.drudis.2007.11.010, 18342802.
7. Fergusen S, Macdonald RL. Predictors of cerebral infarction in patients with aneurysmal subarachnoid hemorrhage. Neurosurgery 2007, 60:658-667.
8. Wong GK, Boet R, Poon WS, Chan MT, Gin T, Ng SC, Zee BC. Intravenous magnesium sulphate for aneurysmal subarachnoid hemorrhage: an updated systemic review and meta-analysis. Crit Care 2011, 15:R52. 10.1186/cc10017, 3221982, 21299874.
9. Dorhout Mees SM, Rinkel GJ, Feigin VL, Algra A, van den Bergh WM, Vermeulen M, van Gijn J. Calcium antagonists for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev 2007, 18:CD000277.
10. Rinkel GJ, Feigin VL, Algra A, van Gijn J. Circulatory volume expansion therapy for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev 2004, 18:CD000483.
11. Zhang S, Wang L, Liu M, Wu B. Tirilazad for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev 2010, 17:CD006778.
12. Suhardja A. Mechanisms of disease: roles of nitric oxide and endothelin-1 in delayed cerebral vasospasm produced by aneurysmal subarachnoid hemorrhage. Nat Clin Pract Cardiovasc Med 2004, 1:110-116. 10.1038/ncpcardio0046, 16265315.
13. Mascia L, Fedorko L, Stewart DJ, Mohamed F, terBrugge K, Ranieri VM, Wallace MC. Temporal relationship between endothelin-1 concentrations and cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage. Stroke 2001, 32:1185-1190. 10.1161/01.STR.32.5.1185, 11340231.
14. Suzuki K, Meguro K, Sakurai T, Saitoh Y, Takeuchi S, Nose T. Endothelin-1 concentration increases in the cerebrospinal fluid in cerebral vasospasm caused by subarachnoid hemorrhage. Surg Neurol 2000, 53:131-135. 10.1016/S0090-3019(99)00179-2, 10713190.
15. Kramer A, Fletcher J. Do endothelin-receptor antagonists prevent delayed neurological deficits and poor outcomes after aneurysmal subarachnoid hemorrhage?: a meta-analysis. Stroke 2009, 40:3403-3406. 10.1161/STROKEAHA.109.560243, 19679843.
16. Macdonald RL, Higashida RT, Keller E, Mayer SA, Molyneux A, Raabe A, Vajkoczy P, Wanke I, Bach D, Frey A, Marr A, Roux S, Kassell N. Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2). Lancet Neurol 2011, 10:618-625. 10.1016/S1474-4422(11)70108-9, 21640651.
17. Jennett B, Bond M. Assessment of outcome after severe brain damage. Lancet 1975, 1:480-484.
18. Sulter G, Steen C, De Keyser J. Use of the Barthel index and modified Rankin scale in acute stroke trials. Stroke 1999, 30:1538-1541. 10.1161/01.STR.30.8.1538, 10436097.
19. Vergouwen MD, Ilodigwe D, Macdonald RL. Cerebral infarction after subarachnoid hemorrhage contributes to poor outcome by vasospasm-dependent and -independent effects. Stroke 2011, 42:924-929. 10.1161/STROKEAHA.110.597914, 21311062.
20. Jaeger M, Schuhmann MU, Soehle M, Nagel C, Meixensberger J. Continuous monitoring of cerebrovascular autoregulation after subarachnoid hemorrhage by brain tissue oxygen pressure reactivity and its relation to delayed cerebral infarction. Stroke 2007, 38:981-986. 10.1161/01.STR.0000257964.65743.99, 17272764.
21. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trial 1996, 17:1-12.
22. Higgins JPT, Green S, . editors Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. editors., http://www.cochrane-handbook.org
23. Shaw MD, Vermeulen M, Murray GD, Pickard JD, Bell BA, Teasdale GM. Efficacy and safety of the endothelin, receptor antagonist TAK-044 in treating subarachnoid hemorrhage: a report by the Steering Committee on behalf of the UK/Netherlands/Eire TAK-044 Subarachnoid Haemorrhage Study Group. J Neurosurg 2000, 93:992-997. 10.3171/jns.2000.93.6.0992, 11117873.
24. Vajkoczy P, Meyer B, Weidauer S, Raabe A, Thome C, Ringel F, Breu V, Schmiedek P. Clazosentan (AXV-034343), a selective endothelin A receptor antagonist, in the prevention of cerebral vasospasm following severe aneurysmal subarachnoid hemorrhage: results of a randomized, double-blind, placebo-controlled, multicenter phase IIa study. J Neurosurg 2005, 103:9-17. 10.3171/jns.2005.103.1.0009, 16121967.
25. Macdonald RL, Kassell NF, Mayer S, Ruefenacht D, Schmiedek P, Weidauer S, Frey A, Roux S, Pasqualin A, . CONSCIOUS-1 Investigators Clazosentan to overcome neurological ischemia and infarction occurring after subarachnoid hemorrhage (CONSCIOUS-1): randomized, double-blind, placebo-controlled phase 2 dose-finding trial. Stroke 2008, 39:3015-3021. 10.1161/STROKEAHA.108.519942, 18688013, CONSCIOUS-1 Investigators.
26. Macdonald RL, Higashida RT, Keller E, Mayer SA, Molyneux A, Raabe A, Vajkoczy P, Wanke I, Bach D, Frey A, Nowbakht P, Roux S, Kassell N. Randomized trial of clazosentan in patients with aneurysmal subarachnoid hemorrhage undergoing endovascular coiling. Stroke 2012, 43:1463-1469. 10.1161/STROKEAHA.111.648980, 22403047.
27. Wartenberg KE, Schmidt JM, Claassen J, Temes RE, Frontera JA, Ostapkovich N, Parra A, Connolly ES, Mayer SA. Impact of medical complications on outcome after subarachnoid hemorrhage. Crit Care Med 2006, 34:617-623.
28. Vergouwen MD, Etminan N, Ilodigwe D, Macdonald RL. Lower incidence of cerebral infarction correlates with improved functional outcome after aneurysmal subarachnoid hemorrhage. J Cereb Blood Flow Metab 2011, 31:1545-1553. 10.1038/jcbfm.2011.56, 3137476, 21505477.
29. Etminan N, Vergouwen MD, Ilodigwe D, Macdonald RL. Effect of pharmaceutical treatment on vasospasm, delayed cerebral ischemia, and clinical outcome in patients with aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis. J Cereb Blood Flow Metab 2011, 31:1443-1451. 10.1038/jcbfm.2011.7, 3130329, 21285966.
30. Vergouwen MD, Vermeulen M, van Gijn J, Rinkel GJ, Wijdicks EF, Muizelaar JP, Mendelow AD, Juvela S, Yonas H, Terbrugge KG, Macdonald RL, Diringer MN, Broderick JP, Dreier JP, Roos YB. Definition of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage as an outcome event in clinical trials and observational studies: proposal of a multidisciplinary research group. Stroke 2010, 41:2391-2395. 10.1161/STROKEAHA.110.589275, 20798370.
31. Kamp MA, Heiroth HJ, Beseoglu K, Turowski B, Steiger HJ, Hänggi D. Early CT perfusion measurement after aneurysmal subarachnoid hemorrhage: a screening method to predict outcome?. Acta Neurochir Suppl 2012, 114:329-332. 10.1007/978-3-7091-0956-4_63, 22327717.